CD133 标志物与晚期非小细胞肺癌患者结局和治疗反应的相关性。

Correlation of CD 133 Biomarker with Outcomes and Therapy Response in Advanced-Stage Non-Small Cell Lung Carcinoma.

机构信息

Pulmonology and Respiratory Medicine Department, Medical Faculty of Hasanuddin University, Makassar, South Sulawesi, Indonesia.

Dr. Wahidin Sudirohusodo Hospital, Makassar, South Sulawesi, Indonesia.

出版信息

Asian Pac J Cancer Prev. 2024 Sep 1;25(9):3315-3325. doi: 10.31557/APJCP.2024.25.9.3315.

DOI:10.31557/APJCP.2024.25.9.3315

PMID:39342612

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11700334/

Abstract

OBJECTIVE

This study aimed to analyze CD 133 stem cell biomarker levels in serum and bronchial lavage, as well as correlate these levels with treatment responses and outcomes in patients with advanced-stage NSCLC.

METHODS

This is a cross-sectional, observational, and analytical study that analyzed data from NSCLC patients and control at Dr. Wahidin Sudirohusodo Hospital, Makassar. CD 133 levels in serum and bronchial lavages were quantified using ELISA and correlated with treatment responses assessed by RECIST 1.1 criteria.

RESULT

A total of 118 participants were used, with 66 being NSCLC patients and 52 as the control. The results showed significant differences in CD 133 serum and bronchial lavage levels (p<0.05). Moreover, NSCLC patients with advanced tumors (T4) had higher CD 133 levels in bronchial wash (p<0.05). The bronchial wash CD 133 test showed higher sensitivity (83.6%) and specificity (79.2%) compared to serum CD 133. Even though CD 133 levels were not significantly correlated with treatment response, they were higher in patients with advanced tumor stages.

CONCLUSION

CD 133 levels were significantly higher in bronchial wash samples from NSCLC patients with advanced tumors (T4). Also, there was a positive correlation between CD 133 levels in bronchial wash and serum. These results emphasized the potential of CD 133, particularly in bronchial wash, as a valuable diagnostic tool for NSCLC.

摘要

目的

本研究旨在分析晚期 NSCLC 患者血清和支气管灌洗液中 CD133 干细胞标志物水平，并将这些水平与治疗反应和结果相关联。

方法

这是一项横断面、观察性和分析性研究，分析了来自望加锡 Wahidin Sudirohusodo 医院的 NSCLC 患者和对照者的数据。使用 ELISA 定量检测血清和支气管灌洗液中的 CD133 水平，并根据 RECIST 1.1 标准评估治疗反应进行相关性分析。

结果

共纳入 118 名参与者，其中 66 名为 NSCLC 患者，52 名为对照组。结果显示，血清和支气管灌洗液中 CD133 水平存在显著差异（p<0.05）。此外，晚期肿瘤（T4）的 NSCLC 患者支气管灌洗液中 CD133 水平更高（p<0.05）。与血清 CD133 相比，支气管灌洗 CD133 检测显示出更高的敏感性（83.6%）和特异性（79.2%）。尽管 CD133 水平与治疗反应无显著相关性，但在晚期肿瘤阶段的患者中水平更高。